PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022. To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/170317 For All Latest Reports Kindly visit: http://www.marketresearchreports.biz

1. PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines Australia Drug
Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the
gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and
effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is
dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis
Menveo, account for the vast majority of global sales, with the US adolescent market being the key target
segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the
launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that
better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market
share during 2012-2022.
GlobalData believes that relative patient share for the three MenC conjugate vaccines available in Australia
will remain unchanged for the duration of the forecast period because Nuron Biotechs Meningitec, Novartis
Menjugate, and Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC
conjugate patient share is largely determined by prescriber preference in Australia and therefore is not
expected to change drastically during the forecast period.
Scope
Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key
drugs in Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Australia from 2012-2022. Analysis of the impact of key events as well the
drivers and restraints affecting Australia Meningococcal Vaccines market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of
the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively
plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make
more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales
forecast for drugs from 2012-2022 in Australia
table Of Contents
1 Table Of Contents 1
1.1 List Of Tables 3
1.2 List Of Figures 3
2 Executive Summary 4
2.1 Sales For Meningococcal Vaccine In Australia 4
2.2 What Do The Physicians Think? 5
3 Introduction 6
PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022

2. 3.1 Catalyst 6
3.2 Related Reports 7
3.3 Upcoming Related Reports 9
4 Disease Overview 9
4.1 Etiology And Pathophysiology 10
4.1.1 Etiology 10
4.1.2 Pathophysiology 11
4.2 Symptoms 13
4.3 Prognosis 14
5 Disease Management 14
5.1 Meningococcal Immunization Policy 15
5.2 Australia 17
5.2.1 Meningococcal Immunization Recommendations And Policies 17
5.2.2 Clinical Practice 19
6 Competitive Assessment 19
6.1 Overview 19
6.2 Strategic Competitor Assessment 20
6.3 Product Profiles Major Brands 21
6.3.1 Menactra 21
6.3.2 Menveo 26
6.3.3 Menitorix 30
6.3.4 Meningitec 33
6.3.5 Menjugate 36
6.3.6 Neisvac-c 39
6.3.7 Menomune 42
6.3.8 Bexsero 45
7 Opportunity And Unmet Need 47
7.1 Overview 47
7.2 Unmet Needs 48
7.2.1 Unmet Need: Protection Against Serogroup B Disease 48
7.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 48
7.2.3 Unmet Need: More Cost-effective Vaccines 50
7.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 50
7.2.5 Unmet Need: Immunogenic Infant Vaccines 52
7.2.6 Unmet Need: Improved Vaccination Coverage Rates 53
7.2.7 Unmet Need: Increased Patient Awareness And Education 54
7.3 Unmet Needs Gap Analysis 55
7.4 Opportunities 56
7.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 56
PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022

3. 7.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 57
7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging
Markets 58
8 Pipeline Assessment 58
8.1 Overview 58
8.2 Promising Vaccines In Clinical Development 58
8.2.1 Mnb Rlp2086 62
8.3 Promising Vaccines In Early Clinical Development 67
8.3.1 Meninge Acyw Conj. 68
8.3.2 Menabcwy 72
8.3.3 Menc Conjugate 75
8.3.4 Heptavalent Dtp-hib-hepb-ipv-menc 78
9 Market Outlook 80
9.1 Australia 80
9.1.1 Forecast 80
9.1.2 Key Events 83
9.1.3 Drivers And Barriers 84
10 Appendix 85
10.1 Bibliography 85
10.2 Abbreviations 97
10.3 Methodology 99
10.4 Forecasting Methodology 99
10.4.1 Vaccine Coverage 100
10.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 100
10.4.3 Vaccines Included 101
10.4.4 General Pricing Assumptions 102
10.4.5 Individual Vaccine Assumptions 103
10.4.6 Pricing Of Pipeline Agents 109
10.5 Physicians And Specialists Included In This Study 110
10.6 About The Authors 114
10.6.1 Authors 114
10.6.2 Reviewers 114
10.6.3 Global Head Of Healthcare 114
10.7 About Globaldata 116
10.8 Contact Us 116
10.9 Disclaimer 116
Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most
comprehensive collection of market research reports. Marketresearchreports.biz services are especially
designed to save time and money of our clients. We are a one stop solution for all your research needs, our
main offerings are syndicated research reports, custom research, subscription access and consulting services.
PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022

4. We serve all sizes and types of companies spanning across various industries.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.com
Website: www.marketresearchreports.biz
PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022